Cargando…

CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

BACKGROUND: Data on recurrence after post-neoadjuvant pancreatectomy are scant. This study investigated the incidence and pattern of recurrence in patients with initially resectable and borderline resectable pancreatic ductal adenocarcinoma who received post-neoadjuvant pancreatectomy. Furthermore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Maggino, Laura, Malleo, Giuseppe, Crippa, Stefano, Belfiori, Giulio, Nobile, Sara, Gasparini, Giulia, Lionetto, Gabriella, Luchini, Claudio, Mattiolo, Paola, Schiavo-Lena, Marco, Doglioni, Claudio, Scarpa, Aldo, Bassi, Claudio, Falconi, Massimo, Salvia, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726670/
https://www.ncbi.nlm.nih.gov/pubmed/36227391
http://dx.doi.org/10.1245/s10434-022-12622-w
_version_ 1784844836928487424
author Maggino, Laura
Malleo, Giuseppe
Crippa, Stefano
Belfiori, Giulio
Nobile, Sara
Gasparini, Giulia
Lionetto, Gabriella
Luchini, Claudio
Mattiolo, Paola
Schiavo-Lena, Marco
Doglioni, Claudio
Scarpa, Aldo
Bassi, Claudio
Falconi, Massimo
Salvia, Roberto
author_facet Maggino, Laura
Malleo, Giuseppe
Crippa, Stefano
Belfiori, Giulio
Nobile, Sara
Gasparini, Giulia
Lionetto, Gabriella
Luchini, Claudio
Mattiolo, Paola
Schiavo-Lena, Marco
Doglioni, Claudio
Scarpa, Aldo
Bassi, Claudio
Falconi, Massimo
Salvia, Roberto
author_sort Maggino, Laura
collection PubMed
description BACKGROUND: Data on recurrence after post-neoadjuvant pancreatectomy are scant. This study investigated the incidence and pattern of recurrence in patients with initially resectable and borderline resectable pancreatic ductal adenocarcinoma who received post-neoadjuvant pancreatectomy. Furthermore, preoperative predictors of recurrence-free survival (RFS) and their interactions were determined. PATIENTS AND METHODS: Patients undergoing post-neoadjuvant pancreatectomy at two academic facilities between 2013 and 2017 were analyzed using standard statistics. The possible interplay between preoperative parameters was scrutinized including interaction terms in multivariable Cox models. RESULTS: Among 315 included patients, 152 (48.3%) were anatomically resectable. The median RFS was 15.7 months, with 1- and 3-year recurrence rates of 41.9% and 74.2%, respectively. Distant recurrence occurred in 83.3% of patients, with lung-only patterns exhibiting the most favorable prognostic outlook. Normal posttreatment CA19.9, ΔCA19.9 (both in patients with normal and elevated baseline levels), and posttreatment tumor size were associated with RFS. Critical thresholds for ΔCA19.9 and tumor size were set at 50% and 20 mm, respectively. Interaction between ΔCA19.9 and posttreatment CA19.9 suggested a significant risk reduction in patients with elevated values when ΔCA19.9 exceeded 50%. Moreover, posttreatment tumor size interacted with posttreatment CA19.9 and ΔCA19.9, suggesting an increased risk in the instance of elevated posttreatment CA19.9 values and a protective effect associated with CA19.9 response in patients with tumor size >20 mm. CONCLUSION: Recurrence following post-neoadjuvant pancreatectomy is common. Preoperative tumor size <20 mm, normal posttreatment CA19.9 and ΔCA19.9 > 50% were associated with longer RFS. These variables should not be taken in isolation, as their interaction significantly modulates the recurrence risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-12622-w.
format Online
Article
Text
id pubmed-9726670
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-97266702022-12-08 CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Maggino, Laura Malleo, Giuseppe Crippa, Stefano Belfiori, Giulio Nobile, Sara Gasparini, Giulia Lionetto, Gabriella Luchini, Claudio Mattiolo, Paola Schiavo-Lena, Marco Doglioni, Claudio Scarpa, Aldo Bassi, Claudio Falconi, Massimo Salvia, Roberto Ann Surg Oncol Pancreatic Tumors BACKGROUND: Data on recurrence after post-neoadjuvant pancreatectomy are scant. This study investigated the incidence and pattern of recurrence in patients with initially resectable and borderline resectable pancreatic ductal adenocarcinoma who received post-neoadjuvant pancreatectomy. Furthermore, preoperative predictors of recurrence-free survival (RFS) and their interactions were determined. PATIENTS AND METHODS: Patients undergoing post-neoadjuvant pancreatectomy at two academic facilities between 2013 and 2017 were analyzed using standard statistics. The possible interplay between preoperative parameters was scrutinized including interaction terms in multivariable Cox models. RESULTS: Among 315 included patients, 152 (48.3%) were anatomically resectable. The median RFS was 15.7 months, with 1- and 3-year recurrence rates of 41.9% and 74.2%, respectively. Distant recurrence occurred in 83.3% of patients, with lung-only patterns exhibiting the most favorable prognostic outlook. Normal posttreatment CA19.9, ΔCA19.9 (both in patients with normal and elevated baseline levels), and posttreatment tumor size were associated with RFS. Critical thresholds for ΔCA19.9 and tumor size were set at 50% and 20 mm, respectively. Interaction between ΔCA19.9 and posttreatment CA19.9 suggested a significant risk reduction in patients with elevated values when ΔCA19.9 exceeded 50%. Moreover, posttreatment tumor size interacted with posttreatment CA19.9 and ΔCA19.9, suggesting an increased risk in the instance of elevated posttreatment CA19.9 values and a protective effect associated with CA19.9 response in patients with tumor size >20 mm. CONCLUSION: Recurrence following post-neoadjuvant pancreatectomy is common. Preoperative tumor size <20 mm, normal posttreatment CA19.9 and ΔCA19.9 > 50% were associated with longer RFS. These variables should not be taken in isolation, as their interaction significantly modulates the recurrence risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-12622-w. Springer International Publishing 2022-10-13 2023 /pmc/articles/PMC9726670/ /pubmed/36227391 http://dx.doi.org/10.1245/s10434-022-12622-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Pancreatic Tumors
Maggino, Laura
Malleo, Giuseppe
Crippa, Stefano
Belfiori, Giulio
Nobile, Sara
Gasparini, Giulia
Lionetto, Gabriella
Luchini, Claudio
Mattiolo, Paola
Schiavo-Lena, Marco
Doglioni, Claudio
Scarpa, Aldo
Bassi, Claudio
Falconi, Massimo
Salvia, Roberto
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
title CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
title_full CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
title_fullStr CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
title_full_unstemmed CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
title_short CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
title_sort ca19.9 response and tumor size predict recurrence following post-neoadjuvant pancreatectomy in initially resectable and borderline resectable pancreatic ductal adenocarcinoma
topic Pancreatic Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726670/
https://www.ncbi.nlm.nih.gov/pubmed/36227391
http://dx.doi.org/10.1245/s10434-022-12622-w
work_keys_str_mv AT magginolaura ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT malleogiuseppe ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT crippastefano ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT belfiorigiulio ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT nobilesara ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT gasparinigiulia ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT lionettogabriella ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT luchiniclaudio ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT mattiolopaola ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT schiavolenamarco ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT doglioniclaudio ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT scarpaaldo ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT bassiclaudio ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT falconimassimo ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma
AT salviaroberto ca199responseandtumorsizepredictrecurrencefollowingpostneoadjuvantpancreatectomyininitiallyresectableandborderlineresectablepancreaticductaladenocarcinoma